Compare Conagra Brands Inc (CAG) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Cronos Group Inc — how do they compare? Conagra Brands Inc trades at $14.93 (market cap $7.07B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Conagra Brands Inc is far larger — about 6.4× Cronos Group Inc's market cap, and Conagra Brands Inc pays a 8.29% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CAG | CRON | |
|---|---|---|
Market Cap | $7.07B | $1.11B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $3.27 |
52-Week Low | $12.58 | $2.30 |
Enterprise Value | $14.12B | $310.67M |
Dividend Yield | 8.29% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
